Traditional therapeutics target the inactive conformation of proteins, allowing tumors to adapt and resume signaling.
REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, ...
Phased review by EMA aims to accelerate assessment of company's investigational drug daraxonrasib in pancreatic cancer based on unprecedented ...
Targeted compound daraxonrasib successfully blocks multiple KRAS variants to double survival limits in clinical trials.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
For roughly four decades, oncologists had a grim shorthand for the most common genetic driver of pancreatic cancer: undruggable. The KRAS protein, mutated in about 90 percent of pancreatic tumors, ...
Simcere Zaiming Pharmaceutical Co. Ltd. has detailed the discovery and preclinical characterization of ZMS-2195, a multiple-RAS inhibitor designed to prevent both mutant and wild-type forms of KRAS, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results